港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

恆瑞醫藥

67.500

+0.8501.28%

成交量：211.77萬

成交額：1.43億

市值：4,479.98億

市盈率：49.91

高：68.750

開：66.300

低：66.300

收：66.650

52周最高：95.200

52周最低：52.500

股本：66.37億

香港流通股本：2.58億

量比：0.22

換手率：0.82%

股息：- -

股息率：- -

每股收益(LYR):1.352

淨資產收益率：14.31%

總資產收益率：8.42%

市淨率：6.38

市盈率(LYR):49.91

市銷率: 12.36

資料載入中...

總覽公司新聞資訊公告

營收316億、淨利增超21% 恒瑞醫藥2025年財報釋放強勁動能

創新藥銷售收入目標增速上調至30%以上，恒瑞醫藥憑什麼?

【券商聚焦】交銀國際維持恒瑞醫藥(01276)中性評級指新品放量+國際化共驅高增長

68家藥企，最新員工薪酬來了（附名單）

Kailera Therapeutics 申請在美國上市

智通港股解盤 | 精準對等反制提振資本信心創新藥密集利好集中爆發

李彥宏、孫飄揚有新職務！

異動解讀 | 恒瑞醫藥盤中大漲5.06%，強勁年報業績與創新藥轉型提振市場信心

恒瑞醫藥創新藥收入佔比近六成 BD重構國際化價值錨點

21世纪经济报道

恒瑞醫藥(600276.SH)：HRS9531注射液獲得藥物臨床試驗批准通知書

恒瑞醫藥新總裁上任後首份年報「雙增」：仿製藥收入下降、遭默克「退貨」暴露隱憂

【灣區早參】深圳：加快智能網聯汽車商業化運營；廣州近3年首店平均年增長率超20%

恒瑞醫藥將於2026年4月16日後派發末期股息每股0.20元

恒瑞醫藥2025年創新業務發力，營收突破316億元，利潤穩步增長

恒瑞醫藥(01276)擬向上海瑞宏迪增資2.85億元

恒瑞醫藥2025年年報：營收淨利再創新高創新國際化雙輪驅動結碩果

21世纪经济报道

仿製藥業務受擠壓，中國製藥商恒瑞季度利潤不及預期

恒瑞醫藥：2025年淨利潤按年增長21.69%，擬10派2元

老虎资讯综合

愛科百發三闖港股今年1月剛獲批首款藥物；ADC藥物頭對頭對比：恒瑞醫藥挑戰德曲妥珠單抗｜掘金創新藥

每日经济新闻

政府委任四名特首顧問團新成員包括恒瑞醫藥(01276.HK)壁仞科技(06082.HK)百度(09888.HK)董事長等

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":67.5,"timestamp":1775808560003,"preClose":66.65,"halted":0,"volume":2117706,"delay":0,"changeRate":0.012753188297074182,"floatShares":258000000,"shares":6637000000,"eps":1.3524345238095237,"marketStatus":"休市中","change":0.85,"latestTime":"04-10 16:09:20","open":66.3,"high":68.75,"low":66.3,"amount":143498924,"amplitude":0.036759,"askPrice":67.6,"askSize":3600,"bidPrice":67.5,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.3524345238095237,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":7,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":66.65,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":0.2173893807149396,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":57.06,"timestamp":1775804400000,"preClose":56.96,"halted":0,"volume":58779400,"delay":0,"premium":"+3.21"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.42%","roe":"14.31%","lyrEps":1.352435,"volumeRatio":0.2173893807149396,"shares":6637000000,"dividePrice":0,"high":68.75,"amplitude":0.036759,"preClose":66.65,"low":66.3,"week52Low":52.5,"pbRate":"6.38","psRate":"12.36","week52High":95.2,"institutionHeld":0,"latestPrice":67.5,"committee":-0.894737,"eps":1.3524345238095237,"divideRate":0,"volume":2117706,"delay":0,"ttmEps":1.3524345238095237,"open":66.3,"prevYearClose":71.25,"prevWeekClose":66.65,"prevMonthClose":64.5,"prevQuarterClose":64.5,"fiveDayClose":64.5,"twentyDayClose":66.45,"sixtyDayClose":77.55,"earningDate":1776873600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-04-23","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776907800000,"name":null,"time":"","dateTimestamp":1776873600000,"actualEps":null},{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1772208000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-04-09","current":49.909995,"percent":0.064516,"low":44.415436,"twenty":51.051893,"median":54.900098,"eighty":60.199931,"high":65.582363,"avg":55.381623,"sd":4.816839,"marketCap":432746667492.65},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42},{"date":"2026-04-02","current":49.302243,"twenty":51.107295,"median":54.905743,"eighty":60.227005,"marketCap":432534434303.11},{"date":"2026-04-09","current":48.948906,"twenty":51.051893,"median":54.900098,"eighty":60.199931,"marketCap":432746667492.65}],"updateTime":1775860628038},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623701399","title":"營收316億、淨利增超21% 恒瑞醫藥2025年財報釋放強勁動能","url":"https://stock-news.laohu8.com/highlight/detail?id=2623701399","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623701399?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 14:37","pubTimestamp":1774852622,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。创新药销售收入163.42亿元，同比增长26.09%，占药品销售收入比重达58.34%；对外许可收入33.92亿元，同比增长25.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260330/32111266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623398522","title":"創新藥銷售收入目標增速上調至30%以上，恒瑞醫藥憑什麼?","url":"https://stock-news.laohu8.com/highlight/detail?id=2623398522","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623398522?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 11:59","pubTimestamp":1774843156,"startTime":"0","endTime":"0","summary":"长坡厚雪，真正的价值，终将被发现。","market":"us","thumbnail":"https://img7.gelonghui.com/column/8.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/8.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4228133","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0012","LU2097828714.EUR","BK0028","LU1064131003.USD","BK0196","600276","BK0188","LU2488822045.USD","LU1255011170.USD","LU2097828557.USD","LU1820825898.SGD","LU1328615791.USD","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU2097828805.USD","LU1580142542.USD","BK1161","LU1997245177.USD","LU1064130708.USD","LU2495084118.USD","LU1146622755.USD","LU0359202008.SGD","LU0359201885.HKD","LU0359201612.USD","LU1997244956.HKD","LU2580892789.USD","BK0239","BK0060","LU2148510915.USD","LU1969619763.USD","159992","LU0405327148.USD","01276","BK1574","LU1655091616.SGD","LU2289578879.USD","LU2580892862.HKD","BK0183","LU2543165471.USD","BK1191","LU1023057109.AUD","LU1781817850.SGD","LU0405327494.USD","06978","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623360351","title":"【券商聚焦】交銀國際維持恒瑞醫藥(01276)中性評級 指新品放量+國際化共驅高增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2623360351","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623360351?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 11:00","pubTimestamp":1774839632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，恒瑞医药(01276)2025年收入同比增长13%，符合该机构的预期，毛利率与2024年基本持平，研发/SG&A费用率下降1.5/1.3ppt，反映公司运营效率的持续提升。2025 年公司业绩录得较快增速，主要动力来自创新药销售持续放量及对外授权收入的常态化贡献。2026年重点关注新进医保产品放量节奏、ADC及减重领域重点品种III期数据读出、及丰厚早研管线产生的更多BD机会。基于2025年业绩及未来指引，该机构微调公司2026-27 年盈利预测，维持目标价 69.5 港元/63.18 人民币（01276/600276 CH），当前估值合理，维持中性评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622844033","title":"68家藥企，最新員工薪酬來了（附名單）","url":"https://stock-news.laohu8.com/highlight/detail?id=2622844033","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622844033?lang=zh_tw&edition=fundamental","pubTime":"2026-03-28 19:04","pubTimestamp":1774695840,"startTime":"0","endTime":"0","summary":"　　同花顺问财数据显示，截至目前，A股已有68家医药企业公布2025年人均薪酬。　　药企年报口径的人均薪酬为全部职工整体人力成本均值，涵盖工资薪金、奖金、社保等各项职工薪酬开支，这一指标可以侧面反映药企行业梯队站位、研发人才储备力度与整体薪酬投入水平。　　具体从各赛道来看，化学制剂赛道中，4家企业人均薪酬跻身高薪酬行列，分别为盟科药业、恒瑞医药、荣昌生物、泽璟制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-28/doc-inhsqhwq5507923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1023057109.AUD","BK1583","LU2543165471.USD","BK1574","01276","09995","BK1161","LU0359201612.USD","LU0359202008.SGD","LU0359201885.HKD","LU2328871848.SGD","LU1969619763.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622194803","title":"Kailera Therapeutics 申請在美國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2622194803","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622194803?lang=zh_tw&edition=fundamental","pubTime":"2026-03-28 05:04","pubTimestamp":1774645483,"startTime":"0","endTime":"0","summary":"路透3月27日 - Kailera Therapeutics公司周五提交了在美国首次公开募股的申请，成为随着该领域上市热潮升温而寻求迎合投资者胃口的最新一家生物技术公司。尽管中东冲突有可能扰乱股市的风险偏好，但美国公司仍在推进首次公开募股计划。由旗舰公司Generate Biomedicines支持的GENB.O上月在纳斯达克首次上市时股价下跌超过6%，给这家药物开发商带来了19.1亿美元的估值。总部位于马萨诸塞州沃尔瑟姆的 Kailera 公司是一家肥胖症药物开发商，致力于帮助患者减肥。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4S40F1N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BK4W5M84.HKD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU0211326755.USD","IE0001KFT4U8.USD","LU0238689110.USD","LU1280957306.USD","LU2552382132.HKD","LU0215105999.USD","LU1551013425.SGD","LU0345769631.USD","LU1244550494.USD","IE00BYXW3230.USD","LU0882574139.USD","LU0786609619.USD","LU2750360997.AUD","BK4588","IE00B4JS1V06.HKD","SG9999014906.USD","LU2361045086.USD","LU1093756168.USD","LU1712237335.SGD","LU2456880835.USD","LU0868494708.USD","BK0183","LU0820561909.HKD","LU0354030511.USD","LU2213496289.HKD","LU0234572021.USD","LU1988902786.USD","BK4566","IE00BKPKM429.USD","LU2054465674.USD","LU0265550359.USD","LU0106831901.USD","IE00BJLML261.HKD","LU2087625088.SGD","LU2168564149.EUR","LU2602419157.SGD","IE0009355771.USD","SG9999001176.SGD","LU2896262040.SGD","IE00BN8TJ469.HKD","IE0034235188.USD","LLY","LU2211815571.USD","IE00BFSS8Q28.SGD","LLII","LU1894683264.USD","LU2106854487.HKD","LU2746668974.SGD","LU0971096721.USD","LU0158827781.USD","LU2271345857.HKD","LU2360106947.USD","LU0345770308.USD","IE00BN29S564.USD","LU0823416689.USD","IE0004445015.USD","LU0417517546.SGD","IE00BDCRKT87.USD","LU2097828557.USD","LU1069344957.HKD","LU2148510915.USD","GB00BDT5M118.USD","LU0251132253.USD","LU1267930730.SGD","BK0012","LU0353189680.USD","LU1116320737.USD","LU2028103732.USD","LU2750360641.GBP","IE0004445239.USD","LU0345769128.USD","LU2756315318.SGD","LLYZ","ELIL","SG9999002232.USD","LU0320765646.SGD","LU2430703251.USD","LU0097036916.USD","LU0096364046.USD","LU0471298694.HKD","LU1244550577.SGD","LU2505996509.AUD","LU1969619763.USD","BK0028","LU2063271972.USD","IE00BHPRN162.USD","LU0070302665.USD","IE0034235295.USD","SG9999013999.USD","LU2097828474.EUR","LU1655091616.SGD","LU0208291251.USD","LU1868837300.USD","LU1720051017.SGD","LU0211327993.USD","LU1868836757.USD","LU0672654240.SGD","ELIS","IE00BFXG1179.USD","LU1997244956.HKD","LU1814569148.SGD","IE00BK4W5L77.USD","LU0058720904.USD","LU1244550221.USD","LU0079474960.USD","LU1232071149.USD","LU0823434740.USD","LU2471134879.HKD","LU1057294990.SGD","LU0149725797.USD","LU2168564065.EUR","LU1868837136.USD","LU0405327494.USD","BK4007","LU2756315664.SGD","LU1162221912.USD","SG9999015986.USD","SG9999015978.USD","SG9999018857.SGD","SG9999014914.USD","LU0820561818.USD","LU1032466523.USD","IE00BKDWB100.SGD","SG9999018865.SGD","LU1328615791.USD","LU1363072403.SGD","BK0188","LU2505996681.GBP","LU2552382058.USD","LU1997245094.SGD","LU0211328371.USD","IE00BJJMRY28.SGD","LU2580892789.USD","LU0943347566.SGD","LU1917777945.USD","LU1670628061.USD","LU2023250330.USD","LU2289578879.USD","IE000M9KFDE8.USD","LU2580892862.HKD","LU0211331839.USD","IE00BKVL7J92.USD","LU1580142542.USD","LU2417539215.USD","LU0289739699.SGD","BK4127","LU1366192091.USD","IE0002141913.USD","LU0320765489.SGD","LU1629891620.HKD","LU0109391861.USD","BK4550","LU1084165304.USD","LU1255011170.USD","LU1820825898.SGD","LU2328871848.SGD","LU0061475181.USD","LU2237438978.USD","IE00BDRTCR15.USD","LU0109394709.USD","LU2592432038.USD","SGXZ51526630.SGD","IE0005OL40V9.USD","IE00BBT3K403.USD","LU2361044865.SGD","IE00B1XK9C88.USD","LU1781817850.SGD","LU2491049909.HKD","LU0122379950.USD","IE00B775SV38.USD","LU2242649171.HKD","BK4504","IE00B1BXHZ80.USD","LU2265009873.SGD","LU2324357040.USD","LU1496350171.SGD","LU0432979614.USD","BK4599","LU0225283273.USD","JPM","LU0203347892.USD","BK0196","IE00BFTCPJ56.SGD","EVR","LU1868836591.USD","600276","LU0048584097.USD","LU2430703178.SGD","LU1064131003.USD","IE00B4R5TH58.HKD","BK0239","LU0320765992.SGD","LU2089284900.SGD","LU2168564495.EUR","LU1146622755.USD","LU1261432733.SGD","SG9999002224.SGD","LU1064131342.USD","LU1145028129.USD","LU0203345920.USD","LU1267930490.SGD","LU1548497426.USD","LU2491050071.SGD","LU2471134523.USD","LU2471134952.CNY","BK0060","LU0823434583.USD","BK4534","SGXZ81514606.USD","IE00BJT1NW94.SGD","LU2491050154.USD","LU2112291526.USD","LU2097828631.EUR","IE00BWXC8680.SGD","BK4581","LU0267386448.USD","LU2089984988.USD","LU2236285917.USD","LU1868836914.USD","LU0210536198.USD","LU1914381329.SGD","LU2111349929.HKD","LU0094547139.USD","LU1291159041.SGD","BK4533","LU1127390331.HKD","LU2495084118.USD","LU2488822045.USD","LU1997245177.USD","IE00BJJMRX11.SGD","LU0106261372.USD","LU0198837287.USD","LU0203201768.USD","IE00B3S45H60.SGD","LU1894683348.USD","SG9999015945.SGD","LU0266013472.USD","LU0882574055.USD","LU0942090050.USD","LU0353189763.USD","LU2237443465.HKD","LU2097828805.USD","LU0345770993.USD","LU0006306889.USD","LU0868494617.USD","IE00BJTD4V19.USD","LU2237443382.USD","LU0114720955.EUR","LU0976567544.SGD","LU2097828714.EUR","LU2552382215.SGD","IE00BFSS7M15.SGD","LU0323591593.USD","IE00B2B36J28.USD","LU0640476718.USD","LU2237443895.HKD","LU0471298777.SGD","IE00BLSP4239.USD","LU1061106388.HKD","SGXZ99366536.SGD","LU1623119135.USD","LU1974910355.USD","LU2381873111.SGD","JPMO","LU0170899867.USD","LU1496350502.SGD","LU2108987350.USD","LU0689472784.USD","LU0708995401.HKD","LU1323610961.USD","LU0211326839.USD","LU2168563687.JPY","LU1804176565.USD","IE00BJTD4N35.SGD","LLYX","LU1668664300.SGD","LU1023059063.AUD","IE00B7KXQ091.USD","LU0256863811.USD","LU0316494557.USD","LU2746668461.USD","BK4585","IE00B775H168.HKD","LU0820562030.AUD","LU0158827948.USD","LU1551013342.USD","IE00BZ1G4Q59.USD","LU2237443978.SGD","LU2023250504.SGD","01276","LU1116320901.HKD","LU1119994496.HKD","LU2089283258.USD","SGXZ31699556.SGD","BK4516","LU1989771016.USD","LU1983299246.USD","LU2237443549.SGD","SG9999017495.SGD","LU0310799852.SGD","LU0385154629.USD","LU0203202063.USD","LU2461242641.AUD","BK4207","LU2023250843.SGD","LU2361044949.HKD","LU0496365809.HKD","LU0787776722.HKD","IE00BLSP4452.SGD","LU0466842654.USD","SG9999015952.SGD","LU2168564222.USD","SGXZ57979304.SGD","IE0034235303.USD","LU0405327148.USD","SG9999014880.SGD","SG9999014898.SGD","LU2357305700.SGD","LU0964807845.USD","LU1064130708.USD","LU2468319806.SGD","LU0265550946.USD","BK4139","LU1720051108.HKD","LU0889565916.HKD","LU1670627923.USD","LU2264538146.SGD","LU0354030438.USD","LU0320765059.SGD","LU2462157665.USD","LU2430703095.HKD","LU0256863902.USD","LU2237443622.USD","LU1035775433.USD","LU1093756325.SGD","LU2023251221.USD","LU2471134796.USD","SG9999001176.USD","LU0683600562.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826595","title":"智通港股解盤 | 精準對等反制提振資本信心 創新藥密集利好集中爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826595","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826595?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 19:44","pubTimestamp":1774611859,"startTime":"0","endTime":"0","summary":"然而，几家美媒援引消息称，伊朗没有提出这一请求，且仍在审议美国的 15点停火方案。伊朗方面消息称，伊朗革命卫队表示，霍尔木兹海峡已关闭，任何通过该水道的船只都将面临“严厉措施 ”。这就是对等反制，关键时机非常好，在美股开市前夕。中国创新药企在国际市场已经占据相当重要的地位，截至 2025 年 12 月 31 日，全球在研且研发状态活跃的创新药共 14088个，中国企业原研药品数量 4751 个 ，超过美国，排名第一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1594","BK1509","BK1574","BK1141","LU1023057109.AUD","01276","SG9999014674.SGD","BK1191","03931","BK1190","LU0359202008.SGD","BK1592","03696","BK1161","LU0359201885.HKD","SG9999006597.SGD","01772","VXUS","LU0359201612.USD","BK1129","02315","06978","09696","159992","BK4585","BK4588","LU2543165471.USD","SG9999003461.SGD","BK1144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622848304","title":"李彥宏、孫飄揚有新職務！","url":"https://stock-news.laohu8.com/highlight/detail?id=2622848304","media":"5D调查","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622848304?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 14:45","pubTimestamp":1774593900,"startTime":"0","endTime":"0","summary":"3月27日消息，香港特区政府近日宣布任命四位特首顾问团新成员，任期自2026年4月1日起生效，至2027年6月30日截止。　　这四位新成员分别是百度集团联合创始人、董事长兼首席执行官李彦宏，江苏恒瑞医药股份有限公司董事长孙飘扬，赛昉半导体科技有限公司创始人兼行政总裁徐滔，壁仞科技创始人、董事长兼首席执行官张文。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/chanjing/wddc/2026-03-27/doc-inhsmhtu5310095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BIDU","LU0417516738.SGD","LU1781817850.SGD","BK4614","LU0762540952.USD","BK1609","LU0164880469.USD","LU0819121731.USD","LU1023057109.AUD","LU0197773160.USD","BK1587","BK0183","BK0196","BK4612","LU0164865239.USD","LU1188198961.HKD","LU1655091616.SGD","LU0640798160.USD","LU1481107354.HKD","LU0417516902.SGD","LU1048596156.SGD","BK4588","BK1575","LU1255011170.USD","LU2097828557.USD","LU2097828714.EUR","LU0229945570.USD","HK0000320223.HKD","LU0287142896.SGD","SG9999014674.SGD","LU0762542818.HKD","LU1969619763.USD","LU0149721374.USD","BK4574","BK4587","LU0831093199.SGD","HK0000306685.HKD","LU0405327148.USD","LU1115378108.SGD","LU2476274308.USD","BK4526","LU0762541174.USD","LU0856984785.SGD","HK0000320264.USD","LU0463099449.HKD","LU0823426480.USD","LU0244354667.USD","LU1820825898.SGD","BIDG","LU0630378692.HKD","LU2580892789.USD","LU0348825331.USD","BK0012","LU2488822045.USD","LU0173614495.USD","LU0228367735.SGD","LU1146622755.USD","LU0315179316.USD","BK1588","LU0051755006.USD","LU2097828474.EUR","LU0405327494.USD","IE0034224299.USD","SG9999002463.SGD","LU2495084118.USD","LU2580892862.HKD","LU1580142542.USD","LU0043850808.USD","BK0060","09888","BK4077","BK4548","01276","LU2778985437.USD","BK0028","LU1328615791.USD","BK1095","LU0543330566.HKD","LU0821914370.USD","LU0823426308.USD","LU0039217434.USD","LU2097828805.USD","HK0000306701.USD","LU1064131003.USD","LU2039709279.SGD","BK0239","LU0197773673.USD","BK4535","BK0188","600276","LU0326950275.SGD","LU0708995583.HKD","BK4514","BK4504","89888","LU0630378429.USD","BK4531","LU0359202008.SGD","LU2148510915.USD","LU0072462343.USD","LU1831875114.USD","LU0348735423.USD","LU0359201612.USD","LU0531971595.HKD","LU0588546209.SGD","LU2289578879.USD","LU2328871848.SGD","LU0320764599.SGD","KBDU","LU1997245094.SGD","IE00B0JY6N72.USD","LU0163747925.USD","BK4579","BK4543","LU1997245177.USD","BK1615","LU1997244956.HKD","LU0456827905.SGD","BK4602","LU0307460666.USD","BK4552","LU1064130708.USD","LU1048588211.SGD","LU0871576103.HKD","LU0052750758.USD","SG9999002828.SGD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1185545662","title":"異動解讀 | 恒瑞醫藥盤中大漲5.06%，強勁年報業績與創新藥轉型提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1185545662","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185545662?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 10:04","pubTimestamp":1774577079,"startTime":"0","endTime":"0","summary":"恒瑞医药今日盘中股价大幅上涨5.06%，引发了市场的广泛关注。消息面上，公司于近日发布了2025年年度报告，业绩表现亮眼。报告显示，公司全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%，增速显著超出行业平均水平。这些积极的财务与战略进展，共同构成了推动股价上涨的核心动力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789788","title":"恒瑞醫藥創新藥收入佔比近六成 BD重構國際化價值錨點","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789788","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622789788?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 07:00","pubTimestamp":1774566000,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药（600276.SH，01276.HK）发布2025年年度报告。财报显示，全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。这一增速显著超出行业平均水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686095212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686095212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0028","LU1146622755.USD","LU1969619763.USD","BK0239","600276","LU2097828714.EUR","LU1997245177.USD","06978","LU1580142542.USD","BK0183","LU0359201612.USD","LU1781817850.SGD","LU1820825898.SGD","LU0405327494.USD","LU2097828557.USD","LU0359202008.SGD","LU2328871848.SGD","BK0060","BK1161","LU1064131003.USD","LU1997244956.HKD","LU2148510915.USD","LU2580892862.HKD","LU1255011170.USD","LU0405327148.USD","LU2289578879.USD","BK0196","BK1574","01276","BK0012","LU1023057109.AUD","LU1328615791.USD","LU0359201885.HKD","LU2580892789.USD","LU2097828805.USD","BK1191","LU1064130708.USD","LU1997245094.SGD","LU1655091616.SGD","LU2097828474.EUR","LU2488822045.USD","159992","LU2097828631.EUR","LU2495084118.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830485","title":"恒瑞醫藥(600276.SH)：HRS9531注射液獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830485","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622830485?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:51","pubTimestamp":1774515073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2026年1月7日受理的HRS9531注射液临床试验申请符合药品注册的有关要求，同意本品开展临床试验。申请的适应症：用于降低动脉粥样硬化性心血管疾病患者的主要心血管不良事件风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","LU2488822045.USD","LU1064130708.USD","LU2097828805.USD","LU2543165471.USD","LU2580892862.HKD","LU1997245094.SGD","LU2148510915.USD","LU2289578879.USD","LU1023057109.AUD","BK1191","LU0359202008.SGD","LU0359201612.USD","01276","LU2580892789.USD","LU2495084118.USD","LU1969619763.USD","BK0188","LU1997244956.HKD","LU1781817850.SGD","BK0183","LU0405327148.USD","LU1997245177.USD","BK0012","LU1328615791.USD","LU2097828631.EUR","BK0060","LU2328871848.SGD","LU1146622755.USD","LU1820825898.SGD","LU1580142542.USD","LU2097828714.EUR","LU1255011170.USD","LU0405327494.USD","BK0196","LU0359201885.HKD","LU1064131003.USD","BK0028","LU1655091616.SGD","600276","LU2097828474.EUR","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622320848","title":"恒瑞醫藥新總裁上任後首份年報「雙增」：仿製藥收入下降、遭默克「退貨」暴露隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2622320848","media":"蓝鲸财经","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622320848?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:11","pubTimestamp":1774512685,"startTime":"0","endTime":"0","summary":"靓丽的财报展示了恒瑞医药这些年在创新药、国际化等领域布局的成功，但赖以发家的仿制药业务却继续出现下滑，拖累业绩增长，此外，今年三月初恒瑞医药去年大力发展的对外授权业务却遭遇重挫，产品被默克“退货”，暴露了高额授权背后的不确定性。创新药销售、对外许可双轮驱动对于营收、利润的增长的原因，恒瑞医药方面称主要系创新药销售收入增长及对外许可收入的确认。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774508291439112391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4534","IE00BJT1NW94.SGD","SG9999002232.USD","LU0130517989.USD","LU0208291251.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1093756168.USD","LU2097828557.USD","01276","LU1116320737.USD","LU1781817850.SGD","BK0196","LU0868494617.USD","BK0012","LU0058720904.USD","LU0985320562.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU0070302665.USD","LU2097828805.USD","LU0965509101.SGD","LU1974910355.USD","LU1035773651.USD","LU1037948897.HKD","LU0477156953.USD","LU2125154935.USD","LU1917777945.USD","LU0266013472.USD","SG9999001176.SGD","LU2097828474.EUR","BK4533","LU1655091616.SGD","IE00BSNM7G36.USD","LU0359201885.HKD","SG9999013999.USD","LU0106261372.USD","LU1061106388.HKD","LU0289739699.SGD","LU2112291526.USD","LU1934455863.HKD","LU2097828631.EUR","LU1997245177.USD","LU0965508806.USD","SG9999014575.USD","LU1255011170.USD","LU1066051498.USD","LU1064130708.USD","LU2361044865.SGD","BK1191","LU1291159041.SGD","LU0861579265.USD","LU1069347547.HKD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU2580892862.HKD","IE0002141913.USD","IE0009355771.USD","LU0211331839.USD","LU2324357040.USD","LU0320765489.SGD","LU0942090050.USD","LU2488822045.USD","LU1023059063.AUD","SG9999002224.SGD","LU1066053197.SGD","LU1699723380.USD","LU1430594728.SGD","LU0405327494.USD","LU0965509283.SGD","LU1983299246.USD","LU2023250843.SGD","LU1571399168.USD","BK0028","LU0098860793.USD","600276","LU0868494708.USD","LU1066051225.USD","LU2125154778.USD","LU0265550359.USD","LU0006306889.USD","LU2097828714.EUR","LU2461242641.AUD","LU1093756325.SGD","LU1934455194.USD","LU0320765646.SGD","LU0234572021.USD","SGXZ57979304.SGD","BK4516","LU2468319806.SGD","LU0130102774.USD","IE000M9KFDE8.USD","LU0965509010.AUD","LU0238689110.USD","LU1969619763.USD","SG9999001440.SGD","LU2543165471.USD","LU1929549753.HKD","BK0188","SG9999014567.USD","LU1066051811.HKD","LU0122379950.USD","BK4007","LU0203345920.USD","SG9999015341.SGD","LU2106854487.HKD","LU1989771016.USD","LU1997244956.HKD","LU1934455277.USD","LU2089984988.USD","LU2361044949.HKD","LU1201861249.SGD","LU1328615791.USD","LU2580892789.USD","LU0203347892.USD","LU1580142542.USD","BK4585","LU1989772923.USD","LU2360032135.SGD","BK4550","BK0060","LU1146622755.USD","LU1162221912.USD","LU2328871848.SGD","LU2023250504.SGD","BK4559","IE00B2B36J28.USD","LU0980610538.SGD","BK0183","BK0239","IE00B4R5TH58.HKD","LU0359201612.USD","LU1023057109.AUD","LU0265550946.USD","LU2361045086.USD","LU0648001328.SGD","LU1064131003.USD","LU1941712348.USD","IE00BJJMRZ35.SGD","LU1941712264.USD","LU1997245094.SGD","LU0359202008.SGD","IE00B1BXHZ80.USD","LU2289578879.USD","SG9999014559.SGD","LU0405327148.USD","LU1057294990.SGD","SG9999015358.SGD","LU1820825898.SGD","BK4588","LU2148510915.USD","SG9999001176.USD","LU1037948541.HKD","LU0432979614.USD","LU2495084118.USD","LU1116320901.HKD","LU1989772840.SGD","SG9999014542.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622688645","title":"【灣區早參】深圳：加快智能網聯汽車商業化運營；廣州近3年首店平均年增長率超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622688645","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622688645?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 08:30","pubTimestamp":1774485010,"startTime":"0","endTime":"0","summary":"方案提出，加快智能网联汽车商业化运营。全年经调整净利润达到206亿元，同比增长16.5%，经调整净利润率为14.5%。期内，公司收入62.3亿港元，同比增长40.9%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977280","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0594300419.USD","MCNHmain","BK1597","LU0315179316.USD","LU0471298777.SGD","LU0173614495.USD","IE0008369823.USD","BK1613","LU0072462343.USD","LU0359201612.USD","BK1531","01958","LU1769817179.HKD","LU0307460666.USD","BK1589","BK1191","BK1539","IE0031814852.USD","03888","BK1521","LU0348788117.USD","MUCmain","LU0588546209.SGD","LU0029875118.USD","BK1526","IE00B29SXG58.USD","LU0228659784.USD","01276","LU0211977185.USD","UCmain","LU1102505929.USD","CYB","LU0823426308.USD","LU0737861699.HKD","LU0326950275.SGD","IE00B031J352.USD","01788","IE00B031HY20.USD","LU0370786039.SGD","02319","LU1051768304.USD","BK1237","BK1104","LU0672654166.SGD","CNHmain","LU0385154629.USD","SG9999002828.SGD","LU0640798160.USD","BK1607","BK1586"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137906506","title":"恒瑞醫藥將於2026年4月16日後派發末期股息每股0.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137906506","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137906506?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 06:35","pubTimestamp":1774478157,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)\n2026年3月25日，恒瑞医药公布，截至2025年12月31日止年度拟派发末期股息，每10股派发2元人民币，即每股0.20元，尚需于2026年4月16日股东大会批准后发放。公司表示，若分红派息记录日公司总股本发生变化，派发方案的每股分配比例将保持不变，并相应调增分配总额。另外，关于港股除净日、股份过户登记的最后时限、记录日期及具体派息日期等事项尚待后续公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138271280","title":"恒瑞醫藥2025年創新業務發力，營收突破316億元，利潤穩步增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1138271280","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138271280?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 06:29","pubTimestamp":1774477778,"startTime":"0","endTime":"0","summary":"恒瑞医药于2025年度实现营业收入316.29亿元，同比增长13.0%；同期录得归属于上市公司股东的利润77.11亿元，同比上升7.7%。报告期内，公司在肿瘤、心血管、免疫和神经系统等多个治疗领域持续深耕，创新药销售收入约163.42亿元，增幅达26.1%，并带动整体业绩稳步提升。公司报告期内在境内外持续推动合作与新药注册申请，提升新产品的临床价值与商业化效率。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622678070","title":"恒瑞醫藥(01276)擬向上海瑞宏迪增資2.85億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622678070","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622678070?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 23:20","pubTimestamp":1774452011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，于2026年3月25日，公司与恒瑞集团、盛迪生物医药基金、深圳迎泰及上海瑞宏迪订立增资协议，以将上海瑞宏迪的注册资本由约人民币1.316亿元增加至约2.303亿元。根据增资协议，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰同意按比例以现金形式出资合共人民币7.5亿元，该公司出资2.85亿元。增资协议完成后，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰将分别继续持有上海瑞宏迪38.0%、28.0%、19.0%及15.0%的股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","LU1997244956.HKD","LU0405327494.USD","LU1023057109.AUD","LU1255011170.USD","LU2148510915.USD","BK0028","LU2097828557.USD","LU1781817850.SGD","LU1064130708.USD","BK0060","LU0359201612.USD","LU1997245177.USD","BK0239","LU1969619763.USD","LU1064131003.USD","LU2328871848.SGD","LU1655091616.SGD","LU1580142542.USD","LU2289578879.USD","LU2488822045.USD","01276","600276","LU1997245094.SGD","LU0359202008.SGD","BK0183","BK1191","LU1146622755.USD","LU2495084118.USD","LU2580892862.HKD","LU2097828714.EUR","BK0196","LU2097828474.EUR","LU2097828805.USD","LU2580892789.USD","LU1820825898.SGD","LU2543165471.USD","LU0405327148.USD","LU0359201885.HKD","LU1328615791.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072044","title":"恒瑞醫藥2025年年報：營收淨利再創新高 創新國際化雙輪驅動結碩果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072044","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072044?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:22","pubTimestamp":1774448520,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253684444032.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684444032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071357","title":"仿製藥業務受擠壓，中國製藥商恒瑞季度利潤不及預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071357","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071357?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445526,"startTime":"0","endTime":"0","summary":"路透上海3月25日 - 中国市值最大的制药企业江苏恒瑞医药600276.SS周三公布的第四季度利润低于市场预期，原因是业务开发交易的收入未能显现。恒瑞在其年报中表示，2025年恒瑞的创新药销售收入增长了26.09%，但仿制药收入有所下滑。该公司年报显示，截至12月31日的一季度，该公司实现归属于股东的净利润19.6亿元，低于汇丰前海证券分析师预计的27亿元。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU2097828557.USD","LU2097828805.USD","LU0070302665.USD","LU0208291251.USD","SG9999014559.SGD","LU0965509283.SGD","LU1255011170.USD","LU1969619763.USD","IE0002141913.USD","LU1035773651.USD","LU0211331839.USD","LU0861579265.USD","SG9999014542.SGD","LU0405327494.USD","LU1585245621.USD","LU0203347892.USD","LU1116320737.USD","01276","LU2361044865.SGD","LU2328871848.SGD","LU1929549753.HKD","IE00BJJMRZ35.SGD","LU0106261372.USD","BK0012","LU0868494708.USD","LU2023250504.SGD","LU0320765489.SGD","LU1571399168.USD","LU1934455194.USD","LU0006306889.USD","LU1037948541.HKD","IE00BSNM7G36.USD","LU0265550946.USD","LU2289578879.USD","IE00B2B36J28.USD","LU1146622755.USD","IE0009355771.USD","LU1066053197.SGD","LU1941712264.USD","LU0130102774.USD","LU1291159041.SGD","LU2361044949.HKD","LU2097828631.EUR","LU2468319806.SGD","600276","SG9999001176.USD","LU2106854487.HKD","LU1064131003.USD","LU2125154778.USD","BK4585","LU1983299246.USD","IE00BLSP4452.SGD","LU2580892789.USD","LU1064130708.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0234572021.USD","BK0239","LU1066051225.USD","LU1917777945.USD","LU0289739699.SGD","LU1061106388.HKD","LU0965508806.USD","IE00BLSP4239.USD","LU1116320901.HKD","LU2361045086.USD","LU0266013472.USD","SG9999015358.SGD","LU0265550359.USD","BK0196","BK4534","LU0122379950.USD","LU2495084118.USD","LU1989772923.USD","LU1066051498.USD","BK0188","LU1201861249.SGD","LU0098860793.USD","SG9999002232.USD","LU2461242641.AUD","LU1069347547.HKD","BK0060","IE00BFTCPJ56.SGD","LU2097828714.EUR","LU2125154935.USD","LU1093756325.SGD","IE00BN8TJ469.HKD","LU0985320562.USD","SG9999014575.USD","LU1162221912.USD","LU1934455277.USD","LU1820825898.SGD","BK4559","LU0320765646.SGD","LU2023250843.SGD","BK4533","BK4588","SG9999014567.USD","LU1430594728.SGD","LU0965509010.AUD","LU0477156953.USD","LU1093756168.USD","LU1941712348.USD","IE00B1BXHZ80.USD","LU1974910355.USD","LU1781817850.SGD","BK0183","SG9999001440.SGD","LU1655091616.SGD","BK0028","SG9999015341.SGD","BK4516","LU0432979614.USD","LU1023059063.AUD","BK4550","LU2112291526.USD","LU0980610538.SGD","LU0868494617.USD","IE00B4R5TH58.HKD","LU0965509101.SGD","LU2089984988.USD","LU1580142542.USD","LU0942090050.USD","SGXZ57979304.SGD","LU1934455863.HKD","LU1989771016.USD","LU2580892862.HKD","LU1057294990.SGD","LU0405327148.USD","LU1066051811.HKD","LU2148510915.USD","LU0238689110.USD","LU2360032135.SGD","LU1997245177.USD","SG9999002224.SGD","SG9999013999.USD","LU1037948897.HKD","IE00BBT3K403.USD","BK4007","LU1997245094.SGD","LU0203345920.USD","LU2488822045.USD","LU2097828474.EUR","LU1699723380.USD","LU0130517989.USD","LU0648001328.SGD","LU1997244956.HKD","LU1328615791.USD","LU0058720904.USD","LU2324357040.USD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167610912","title":"恒瑞醫藥：2025年淨利潤按年增長21.69%，擬10派2元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167610912","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167610912?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:47","pubTimestamp":1774442842,"startTime":"0","endTime":"0","summary":"3月25日，$恒瑞医药(01276)$公告称，2025年公司实现营收316.29亿元，同比增长13.02%；净利润77.11亿元，同比增长21.69%。拟向全体股东按每10股派发现金股利2.00元（含税）。小财注：Q3净利润13.01亿，据此计算，Q4净利润19.6亿，环比增长50%。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药：2025年净利润同比增长21.69%，拟10派2元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","LU1023057109.AUD","LU2097828805.USD","LU2580892862.HKD","BK0239","LU2097828474.EUR","LU0405327494.USD","BK0060","LU1997245177.USD","LU2580892789.USD","BK0196","LU1328615791.USD","BK0012","LU0405327148.USD","LU1820825898.SGD","LU1580142542.USD","LU0359202008.SGD","LU1064131003.USD","LU2148510915.USD","LU2097828714.EUR","LU1997245094.SGD","LU2328871848.SGD","LU2289578879.USD","BK0028","BK0183","LU1064130708.USD","LU0359201612.USD","LU0359201885.HKD","LU1969619763.USD","LU1255011170.USD","LU1997244956.HKD","LU2495084118.USD","BK1191","LU1146622755.USD","LU2097828631.EUR","01276","LU1781817850.SGD","LU2543165471.USD","BK0188","LU2097828557.USD","LU1655091616.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621093082","title":"愛科百發三闖港股 今年1月剛獲批首款藥物；ADC藥物頭對頭對比：恒瑞醫藥挑戰德曲妥珠單抗｜掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093082","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621093082?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 22:16","pubTimestamp":1774361773,"startTime":"0","endTime":"0","summary":"一周行情上周（3月16日至3月20日）医药生物指数下跌1.38%，跑赢上证指数2个百分点。创新药（BK1106）周内下跌3.57%；恒生医疗保健业指数（HSCICH）周内下跌0.33%；港股创新药ETF（513120）周内下跌0.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682906186.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682906186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU2289578879.USD","LU2097828557.USD","BK4588","LU2580892789.USD","06978","LU0405327494.USD","LU2495084118.USD","LU1146622755.USD","ADC","LU0359202008.SGD","LU1820825898.SGD","01276","BK0188","LU1580142542.USD","BK0183","LU1969619763.USD","LU1655091616.SGD","LU1997245177.USD","LU1064131003.USD","BK4080","LU0405327148.USD","LU1064130708.USD","LU1781817850.SGD","LU2328871848.SGD","LU1255011170.USD","LU2543165471.USD","BK4585","BK4231","LU1023057109.AUD","LU2097828631.EUR","600276","159992","LU1997245094.SGD","LU2097828805.USD","LU0359201612.USD","BK0012","LU0359201885.HKD","BK1161","BK0028","LU2148510915.USD","LU2580892862.HKD","VXUS","LU2097828474.EUR","LU1328615791.USD","LU2488822045.USD","BK0239","BK0060","BK1574","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063001","title":"政府委任四名特首顧問團新成員  包括恒瑞醫藥(01276.HK)壁仞科技(06082.HK)百度(09888.HK)董事長等","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063001","media":"阿斯达克财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063001?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 18:11","pubTimestamp":1774347060,"startTime":"0","endTime":"0","summary":"政府今日宣布委任四名特首顾问团新成员。有关任期由今年4月1日起生效，至明年6月30日止，包括恒瑞医药董事长孙飘扬、赛昉科技创始人兼CEO徐滔、壁仞科技创始人、董事长、CEO张文，以及百度-SW联合创始人、董事长兼CEO李彦宏。获委任的新成员均是硬科技及生命科技等前沿领域的业界翘楚，他们的参与将进一步拓展特首顾问团的专业领域。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220802135129703_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220802135129703_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511951/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511951/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0315179316.USD","LU0072462343.USD","LU0307460666.USD","LU0320764599.SGD","LU1023057109.AUD","LU0831093199.SGD","LU1781817850.SGD","LU0359202008.SGD","LU0052750758.USD","LU0588546209.SGD","LU0762540952.USD","LU0417516738.SGD","SG9999014674.SGD","LU0164865239.USD","LU0287142896.SGD","LU0543330566.HKD","BK1609","LU0856984785.SGD","HK0000320264.USD","LU0456827905.SGD","LU0762541174.USD","BK0196","LU0164880469.USD","LU1048596156.SGD","LU0630378692.HKD","LU1969619763.USD","SG9999002828.SGD","LU0197773160.USD","BK0028","LU0640798160.USD","BK1587","600276","LU0359201612.USD","LU2543165471.USD","LU2097828474.EUR","LU1655091616.SGD","LU1048588211.SGD","LU1064131003.USD","BK1095","BK0239","BK1615","09888","01276","LU1146622755.USD","89888","LU0821914370.USD","LU1115378108.SGD","LU1997244956.HKD","LU2778985437.USD","LU0326950275.SGD","BK0183","LU0197773673.USD","LU0823426480.USD","BK0060","LU0173614495.USD","LU0417516902.SGD","HK0000306685.HKD","LU0405327494.USD","BK1191","LU0039217434.USD","LU2476274308.USD","BK1163","LU0359201885.HKD","LU2097828631.EUR","LU1188198961.HKD","BIDU","LU0463099449.HKD","06082","SG9999002463.SGD","LU0229945570.USD","LU0819121731.USD","LU0823426308.USD","LU2495084118.USD","LU2488822045.USD","LU0348735423.USD","LU0051755006.USD","LU1328615791.USD","BK0188","LU1997245177.USD","LU0762542818.HKD","LU1997245094.SGD","LU2580892789.USD","HK0000320223.HKD","LU0708995583.HKD","LU0405327148.USD","LU2289578879.USD","LU0043850808.USD","BK1575","LU1064130708.USD","LU1481107354.HKD","LU2097828805.USD","LU2580892862.HKD","LU0871576103.HKD","LU1580142542.USD","BK1588","LU0531971595.HKD","LU2039709279.SGD","LU0149721374.USD","LU2097828557.USD","LU0228367735.SGD","LU0244354667.USD","LU2148510915.USD","LU0348825331.USD","IE0034224299.USD","LU0630378429.USD","LU2097828714.EUR","HK0000306701.USD","LU1831875114.USD","LU1255011170.USD","LU1820825898.SGD","LU2328871848.SGD","BK0012","LU0163747925.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}